Public Release: 

AutovaxID™-C introduced by Accentia Biopharmaceuticals

Automated instrumentation marks major breakthrough for vaccine production and personalized medicine

SciWords

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced that its subsidiary, Biovest International, Inc., presented its newest cell culture instrument, the AutovaxIDTM-C, at the Cancer Research Institute's recent meeting, "Cancer Vaccines: Barriers, Endpoints and Opportunities." This was the first introduction of the AutovaxID-C to the biotech industry.

The AutovaxID-C is an automated hollow fiber cell culture instrument that collects secreted protein from cells and controls the growth of the cells automatically for 30 days or more. Growth takes place in sterile, disposable patient specific modules that are bar coded for ease of tracking and identification. Biovest believes that the AutovaxID-C instrument represents a significant advance in personalized medicine because it reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches. Further expected advantages include reduced manpower requirements, automated batch record generation and improved efficiency in facility design.

"Cancer vaccines are one of the most exciting and promising fields of personalized medicine," said Carl M. Cohen, Ph.D., Chief Operating Officer, Biovest. "The production of a patient specific vaccine to immunize individuals against their own cancers has been a goal of investigators in both academia and industry. Biovest is currently testing an idiotype vaccine to treat follicular non-Hodgkin's lymphomas in a Phase 3 clinical trial."

"Our approach is unique in that it uses hybridoma technology to produce complete idiotype proteins identical to those on the tumor B cells. Results from early clinical trials are very encouraging and generating a lot of excitement in the medical community; however, there has been some concern about the challenge of producing personalized vaccines on a large scale. At this meeting we presented the first of a suite of instruments, designed and produced by the Biovest Advanced Instrumentation Division, that automates many of the steps involved in hybridoma-based manufacturing. We believe that our new instruments will facilitate the large-scale manufacture of personalized vaccines. We also believe that there is a significant market potential for this instrument," said Dr. Cohen.

About Accentia Biopharmaceuticals: Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. The company's SinuNaseTM product is a novel application and formulation of a known anti-fungal being developed under an Investigational New Drug Application (IND) to treat chronic sinusitis (rhinosinusitis). SinuNase was originally developed by and licensed from the Mayo Foundation for Medical Education and Research. BiovaxIDTM is a patient-specific anti-cancer vaccine intended for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID is being developed by Accentia's subsidiary Biovest International, Inc. and it is currently in a pivotal Phase 3 clinical trial started by the National Cancer Institute. In addition, Accentia has a growing specialty pharmaceutical business with a portfolio of currently marketed products plus a pipeline of additional products under development by third parties. For further information, please visit Accentia's website: www.accentia.net

About Biovest International: Biovest International (OTCBB:BVTI.OB) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest has a foundation in the manufacture of biologics for research and for clinical trials. In addition, Biovest develops, manufactures, and markets patented cell culture systems including the AutovaxID which is being developed as a automated vaccine manufacturing instrument. Biovest's therapy for follicular non-Hodgkin's lymphoma, BiovaxIDTM, is currently in Phase 3 pivotal clinical trial at over 20 major centers in the US being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. For further information, please visit Biovest's website: www.biovest.com

###

Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about AutovaxID, BiovaxID and any other statements relating to Accentia's products, product candidates, and product development programs. Such statement may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Accentia's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of Accentia's clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in Accentia's filings with the Securities and Exchange Commission. All forward looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact: Sherran Brewer, 866-481-9020, email: sbrewer@accentia.net

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.